Evaluating the characteristics and the management of patients with neuroendocrine tumors receiving octreotide LAR during a 6-year period

Pancreas

Volumn 40, Issue 7, 2011, Pages 987-994

  Anthony, Lowell ^a   Vinik, Aaron I ^b  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

carcinoid; diarrhea; flushing; neuroendocrine tumor; octreotide

Indexed keywords

OCTREOTIDE;

ADULT; AGED; ARTICLE; BRONCHOSPASM; CANCER SURGERY; CARCINOID SYNDROME; CHOLECYSTITIS; CHOLELITHIASIS; DIARRHEA; FEMALE; FLUSHING; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; STEATORRHEA; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MALIGNANT CARCINOID SYNDROME; MIDDLE AGED; NEUROENDOCRINE TUMORS; OCTREOTIDE; PHYSICIAN'S PRACTICE PATTERNS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 80052965389     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e31821f66b4     Document Type: Article

References (32)

1. Kaltsas GA, Besser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev. 2004;25:458-511. (Pubitemid 38780668)
2. Robertson RG, Geiger WJ, Davis NB. Carcinoid tumors. Am Fam Physician. 2006;74:429-434. (Pubitemid 44285162)
3. Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063-3072.
4. Horton KM, Kamel I, Hofmann L, et al. Carcinoid tumors of the small bowel: A multitechnique imaging approach. AJR Am J Roentgenol. 2004;182:559-567. (Pubitemid 38269509)
5. van der Lely AJ, de Herder WW. Carcinoid syndrome: Diagnosis and medical management. Arq Bras Endocrinol Metabol. 2005;49:850-860.
6. Campana D, Nori F, Piscitelli L, et al. Chromogranin A: Is it a useful marker of neuroendocrine tumors? J Clin Oncol. 2007;25:1967-1973. (Pubitemid 46972778)
7. Vinik A, Feliberti E, Perry R, et al. Carcinoid tumors (Chapter 2). In: Vinik A, ed. Diffuse Hormonal Systems and Endocrine Tumor Syndromes. 2009. Available at: Http://www.endotext.org/guthormones/guthormone2/guthormoneframe2. htm. Accessed May 11, 2011.
8. Delaunoit T, Rubin J, Neczyporenko F, et al. Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumors. Mayo Clin Proc. 2005;80:502-506. (Pubitemid 40471383)
9. Hedinger C, Gloor R. Metastasizing carcinoid of the small intestine, tricuspid valve disease and pulmonary stenosis, a new syndrome [in German]. Schweiz Med Wochenschr. 1954;84:942-946.
10. Bauer W, Briner U, Doepfner W, et al. SMS 201-995: A very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci. 1982;31:1133-1140. (Pubitemid 13243115)
11. Modlin IM, Latich I, Kidd M, et al. Therapeutic options for gastrointestinal carcinoids. Clin Gastroenterol Hepatol. 2006;4: 526-547.
12. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97:934-959. (Pubitemid 36173145)
13. Joseph S, Li G, Lindholm E, et al. A prospective trial on the effect of body mass index and sex on plasma octreotide levels in patients undergoing long-term octreotide LAR therapy. Pancreas. 2010; 39:964-966.
14. Hofland LJ, Lamberts SW. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev. 2003;24:28-47. (Pubitemid 36223278)
15. Van der Horst-Schrivers AN, Wymenga AN, Links TP, et al. Complications of midgut carcinoid tumors and carcinoid syndrome. Neuroendocrinology. 2004;80(suppl 1):28-32.
16. Zuetenhorst JM, Bonfrer JM, Korse CM, et al. Carcinoid heart disease: The role of urinary 5-hydroxyindoleacetic acid excretion and plasma levels of atrial natriuretic peptide, transforming growth factor-beta and fibroblast growth factor. Cancer. 2003;97:1609-1615. (Pubitemid 36350703)
17. Zuetenhorst JM, Korse CM, Bonfrer JM, et al. Role of natriuretic peptides in the diagnosis and treatment of patients with carcinoid heart disease. Br J Cancer. 2004;90:2073-2079. (Pubitemid 38869708)
18. Lundin L, Norheim I, Landelius J, et al. Carcinoid heart disease: Relationship of circulating vasoactive substances to ultrasound-detectable cardiac abnormalities. Circulation. 1988; 77:264-269. (Pubitemid 18060033)
19. Howard RJ, Drobac M, Rider WD, et al. Carcinoid heart disease: Diagnosis by two-dimensional echocardiography. Circulation. 1982;66:1059-1065. (Pubitemid 12036841)
20. Lundin L, Landelius J, Andren B, et al. Transoesophageal echocardiography improves the diagnostic value of cardiac ultrasound in patients with carcinoid heart disease. Br Heart J. 1990;64:190-194. (Pubitemid 20269059)
21. Robiolio PA, Rigolin VH, Wilson JS, et al. Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography. Circulation. 1995;92:790-795.
22. Rubin J, Ajani J, Schirmer W, et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol. 1999;17:600-606. (Pubitemid 29075248)
23. Ostchega Y, Yoon SS, Hughes J, et al. Hypertension awareness, treatment, and controlYcontinued disparities in adults: United States, 2005-2006. NCHS Data Brief. 2008;1-8.
24. Whitman HH III, Fishman EK, Oberg K, et al. Catecholamine-secreting metastatic carcinoid as differential diagnosis in pheochromocytoma: Clinical, laboratory, and imaging clues in the search for the lurking neuroendocrine tumor (NET). Ann N Y Acad Sci. 2006;1073:59-78. (Pubitemid 44911999)
25. Takiyyuddin MA, Parmer RJ, Kailasam MT, et al. Chromogranin A in human hypertension. Influence of heredity. Hypertension. 1995; 26:213-220.
26. Zhang K, Rao F, Wen G, et al. Catecholamine storage vesicles and the metabolic syndrome: The role of the chromogranin A fragment pancreastatin. Diabetes Obes Metab. 2006;8:621-633. (Pubitemid 44515559)
27. Department of Health and Human ServicesVCenters for Disease Control and Prevention. National Diabetes Fact Sheet, 2007. Available at: Http://www.cdc.gov/diabetes/pubs/pdf/ndfs-2007.pdf. Accessed August 14, 2009.
28. Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9:61-72.
29. Arnold R, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study of the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID study group. ASCO GI Cancers Symposium. 2009. Abstract 121.
30. Rinke A, Muller H-H, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study of the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID study group. J Clin Oncol. 2009;27:4656-4663.
31. Vinik AI, Anthony L, Boudreaux JP, et al. Neuroendocrine tumors: A critical appraisal of management strategies. Pancreas. 2010;39:801-818.
32. Yao JC, Lombard-Bohas C, Baudin E, et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: A phase II trial. J Clin Oncol. 2010;28:69-76.